Biovica International AB (publ) (FRA:9II)

Market Cap	13.74M
Revenue (ttm)	852.38K
Net Income (ttm)	-7.38M
Shares Out	n/a
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700
Average Volume	n/a
Open	0.0180
Previous Close	0.0184
Day's Range	0.0180 - 0.0180
52-Week Range	0.0146 - 0.2350
Beta	n/a
RSI	43.14
Earnings Date	Dec 18, 2025

About Biovica International AB

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 27
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9II

Financial Performance

In 2025, Biovica International AB's revenue was 8.65 million, an increase of 18.53% compared to the previous year's 7.30 million. Losses were -87.62 million, -29.80% less than in 2024.

Financial numbers in SEK